α-lipoic acid-based PPARγ agonists for treating inflammatory skin diseases

Archives of Dermatological Research

Volumn 296, Issue 3, 2004, Pages 97-104

  Venkatraman, Meenakshi S ^a   Chittiboyina, Amar ^a   Meingassner, Josef ^b   Ho, Christopher I ^c   Varani, James ^d   Ellis, Charles N ^d   Avery, Mitchell A ^a   Pershadsingh, Harrihar A ^e,f   Kurtz, Theodore W ^g,h   Benson, Stephen C ^c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b Novartis Forschungsinstitut GmbH   (Austria)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e KERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Bethesda Pharmaceuticals Inc   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lipoic acid; Dermatitis; Inflammation; Peroxisome proliferator activated receptor ; Psoriasis; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BP 1003; BP 1008; BP 1009; BP 1010; BP 1017; CYTOKINE; INTERLEUKIN 2; N [2 [4 [2,4 DIOXO (1,3 THIAZOLIDIN 5 YL)METHYL]PHENOXY]ETHYL] 5 (1,2 DITHIOLAN 3 YL) N METHYLPENTANAMIDE; OXAZOLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CONTACT DERMATITIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; KERATINOCYTE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SKIN DISEASE;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CELL DIVISION; DERMATITIS, ALLERGIC CONTACT; DISEASE MODELS, ANIMAL; HAPLORHINI; HUMANS; INTERLEUKIN-2; KERATINOCYTES; MICE; PPAR GAMMA; T-LYMPHOCYTES; THIAZOLES; THIOCTIC ACID;

EID: 4344693085     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-004-0480-5     Document Type: Article

References (36)

1. Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome proliferator- activated receptor-gamma and metabolic disease. Annu Rev Biochem 70:341-367
2. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550
3. Debril MB, Renaud JP, Fajas L, Auwerx J (2001) The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 79:30-47
4. Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator- activated receptors in inflammation control. J Endocrinol 169:453-459
5. Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M (2001) Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 423:1-7
6. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW (1993) Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21:1020-1033
7. Pershadsingh HA (1999) Pharmacological peroxisome proliferator-activated receptor-gamma ligands: emerging clinical indications beyond diabetes. Expert Opin Investig Drugs 8:1859-1872
8. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan JK, Amin NM (1998) Treatment of psoriasis with troglitazone therapy. Arch Dermatol 134:1304-1305
9. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW (2000) Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136:609-616
10. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin C (1988) Insulin-like growth factor I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 263:9402-9408
11. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A (1997) A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137:568-576
12. Rosen E, Sarraf P, Troy A, Bradwin G, Moore K, Milstone D, Spiegelman B, Mortensen R (1999) Activated PPARγ is required for differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956
14. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ (2000) The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164:1364-1371
15. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ (2002) Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 168: 2795-2802
16. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
17. Altiok S, Xu M, Spiegelman BM (1997) PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11:1987-1998
18. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA (1997) Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 10:440-446
19. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83:1097-1103
20. Yang XY, Wang LH, Mihalic K, Xiao W, Chen T, Li P, Wahl LM, Farrar WL (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor (PPAR) agonists: PPAR co-association with transcription factor NFAT. J Biol Chem 275:4541-4544
21. Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22:937-944
22. Malhotra S, Shafiq P, Pandhi P, Kumar B, Jain R, Aggarwal M (2002) Pioglitazone versus placebo in patients with plaque psoriasis: pilot trial study design and preliminary results. J Clin Pharmacol 42:1053-1061
23. Biewenga GP, Haenen GR, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29:315-331
24. Packer L, Witt EH, Tritschler HJ (1995) α-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19:227-250
25. Van Ruissen F, Van de Kerkhof PC, Schalkwijk J (1995) Signal transduction pathways in epidermal proliferation and cutaneous inflammation. Clin Dermatol 13:161-190
26. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans R (2001) PPAR-gamma dependent and independent effects on macrophage gene expression in lipid metabolism and inflammation. Nat Med 7:48-52
27. Saah M, Wu WM, Eberst K, Marvanyos E, Bodor N (1996) Design, synthesis, pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue. J Pharm Sci 85:496-504
28. Serhan CN, Devchand PR (2001) Novel anti-inflammatory targets for asthma. A role for PPARgamma? Am J Respir Cell Mol Biol 24:658-661
29. Hashimoto Y, Nakahara K (2002) Improvement of asthma after administration of pioglitazone. Diabetes Care 25:401-408
30. Woerly G, Honda K, Loyens M, Pain J, Auwerx J, Staels B, Capron M, Dombrowicz D (2003) Peroxisome proliferator-activated receptors α and γ down regulate allergic inflammation and eosinophil activation. J Exp Med 198:411-4121
31. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y (2001) Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456
32. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K (2000) Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 36:1529-1535
33. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Kurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD (2001) An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96:3323-3328
34. Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE, Hinton DR (2001) Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 119:709-717
35. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR (2000) Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41:2309-2317
36. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51:694-702